NR ASTO
AU Haik,S.; Brandel,J.P.; Salomon,D.; Sazdovitch,V.; Delasnerie-Laupretre,N.; Laplanche,J.L.; Faucheux,B.A.; Soubrie,C.; Boher,E.; Belorgey,C.; Hauw,J.J.; Alperovitch,A.
TI Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects
QU Neurology 2004 Dec 28; 63(12): 2413-5
KI Neurology. 2005 May 24;64(10):1824; author reply 1824. PMID: 15911834
PT journal article
AB Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt-Jakob disease (CJD). The authors report the results of an open compassionate procedure to which 32 CJD patients had access. In some genotypic subgroups, a slight but nonsignificant increase in survival was observed, likely due to biased inclusion of long-term surviving patients. There was no pathologic evidence of a beneficial effect of quinacrine treatment.
MH Brain/pathology; Creutzfeldt-Jakob Syndrome/*drug therapy/mortality/pathology; Disease Progression; Drug Evaluation; Humans; Quinacrine/administration & dosage/adverse effects/*therapeutic use; Research Support, Non-U.S. Gov't; Survival Analysis; Treatment Failure
AD Raymond Escourolle Neuropathology Laboratory, INSERM U360, Salpetriere Hospital, 47, bd de l'Hopital, 75651 Paris Cedex 13, France. haik@chups.jussieu.fr
SP englisch
PO USA